Vertex Pharmaceuticals presents vanzacaftor/tezacaftor/deutivacaftor data
Vertex Pharmaceuticals announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor – the potential next-in-class triple combination medicine – will take place at the North American Cystic Fibrosis Conference, or NACFC. Vertex also announced presentations describing long-term outcomes in people with cystic fibrosis ages 2 to 11 years taking Trikafta, demonstrating consistent and sustained improvements across multiple measures of disease. Vertex will present data on the vanza triple in an oral presentation and two posters on Friday, September 27. This is the first time that the clinical data from the Phase 3 clinical trials of the vanza triple in patients six years and older with CF have been accepted for presentation at a medical meeting. These data formed the basis of global regulatory submissions. Vertex will present new data on Trikafta from long-term studies in patients ages 2-11 years old that reinforce the sustained benefit seen in studies in older people with CF. Specifically, that early treatment with Trikafta is associated with sustained improvements in lung function. These new data demonstrate that in these young children, Trikafta could also lead to improved exocrine pancreatic function over time. The data presented at NACFC highlight the safety and tolerability of Trikafta, which were generally consistent with the established safety profile. Vertex will have four poster presentations that include clinical trial and real-world evidence data, three specifically on Trikafta and one showing sustained benefits from Kalydeco, which is approved for treatment in the youngest ages.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX: